Nigel Davies
Overview
Explore the profile of Nigel Davies including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
22.
Gennemark P, Walter K, Clemmensen N, Rekic D, Nilsson C, Knochel J, et al.
Sci Transl Med
. 2021 May;
13(593).
PMID: 33980578
Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 inhibitors are administered via subcutaneous injection. We present...
23.
Davies N, Hovdal D, Edmunds N, Nordberg P, Dahlen A, Dabkowska A, et al.
Mol Ther Nucleic Acids
. 2021 Apr;
24:369-384.
PMID: 33868782
Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient...
24.
Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnurch A, et al.
Adv Drug Deliv Rev
. 2021 Feb;
171:289-331.
PMID: 33610694
Although oral drug delivery is the preferred administration route and has been used for centuries, modern drug discovery and development pipelines challenge conventional formulation approaches and highlight the insufficient mechanistic...
25.
Novak J, Zarinabad N, Rose H, Arvanitis T, MacPherson L, Pinkey B, et al.
Sci Rep
. 2021 Feb;
11(1):2987.
PMID: 33542327
To determine if apparent diffusion coefficients (ADC) can discriminate between posterior fossa brain tumours on a multicentre basis. A total of 124 paediatric patients with posterior fossa tumours (including 55...
26.
Berg S, Krause J, Bjorkbom A, Walter K, Harun S, Granfeldt A, et al.
J Pharm Sci
. 2020 Nov;
110(1):228-238.
PMID: 33212160
In this study a 3D printed capsule designed to break from the physiological pressures in the antropyloric region was evaluated for its ability to deliver the synthetic octapeptide octreotide in...
27.
Gallagher K, Raghuram A, Williams G, Davies N
Eye (Lond)
. 2020 Oct;
35(10):2899-2900.
PMID: 32999475
No abstract available.
28.
Marshall E, Robertson M, Kam S, Penwarden A, Riga P, Davies N
Eye (Lond)
. 2020 Jul;
35(1):358.
PMID: 32690923
No abstract available.
29.
Sawlani V, Patel M, Davies N, Flintham R, Wesolowski R, Ughratdar I, et al.
Insights Imaging
. 2020 Jul;
11(1):84.
PMID: 32681296
MRI has a vital role in the assessment of intracranial lesions. Conventional MRI has limited specificity and multiparametric MRI using diffusion-weighted imaging, perfusion-weighted imaging and magnetic resonance spectroscopy allows more...
30.
Marshall E, Robertson M, Kam S, Penwarden A, Riga P, Davies N
Eye (Lond)
. 2020 Jun;
35(1):343-348.
PMID: 32587388
Introduction: To measure the prevalence of hydroxychloroquine retinopathy in patients attending a hydroxychloroquine monitoring service using 2018 Royal College of Ophthalmologists diagnostic criteria. Methods: A service evaluation audit of a...